Infectious Diseases

Moderna Therapeutics has announced the positive results of trials of its COVID-19 vaccine, mRNA-1273.   The results of interim Phase I clinical trial showed promising outcomes in terms of efficacy and tolerability and potential of mRNA-1273 against COVID-19. The company received the funds for conducting trials from Biomedical Advanced Research and Development Authority (BARDA) and is developing the vaccine along with the U.S. National Institute of Allergy and Infectious Diseases (NIAID).  The trials tested the ability of the vaccine to trigger immune responses against the coronavirus – SARS-CoV-2. Data for doses 25 ug and 100 ug in which the immun...